China’s latest National Reimbursement Drug List (NRDL), set to take effect on January 1, 2026, is reshaping competitive dynamics across oncology, rare disease, and chronic metabolic care, as a wave of domestic and multinational companies secured new listings or renewed coverage for some of their highest-priority medicines. The update coincides with the release of the … Read more
Merck’s plan to introduce a subcutaneous formulation of Keytruda in Germany has been halted after a Munich court issued a preliminary injunction siding with Halozyme’s patent infringement claims.
Innovent Biologics closed out the year with one of its most consequential access wins to date, securing National Reimbursement Drug List (NRDL) inclusion for seven innovative medicines spanning oncology, immunology, metabolism, and rare disease. The breadth of updates underscores how the company’s maturing R&D engine, lifecycle management strategy, and pricing discipline are converging to generate … Read more
Germany has cleared the way for pharmacy-level substitution of prescribed biologics with lower-cost biosimilars starting in 2026.
The U.S. and U.K. have reached an agreement in principle that lifts U.K. net prices for new innovative medicines by 25 percent, caps VPAG repayments at 15 percent from 2026 onward, and exempts U.K.-origin pharmaceutical and medical goods from Section 232 tariffs.
CMS has issued its final payment determination for Pillar Biosciences’ oncoReveal CDx, confirming a crosswalk-based national rate of $1,352.09, service beginning January 1, 2026. The decision, which aligns with CMS’ preliminary ruling from August, marks a meaningful advance for Medicare beneficiaries and reinforces oncoReveal CDx’s position as a front-line, multi-cancer NGS testing kit in the … Read more
Omeros has finalized the handoff of its clinical-stage MASP-3 monoclonal antibody zaltenibart (OMS906) to Novo Nordisk, closing a transaction that delivers immediate liquidity, removes near-term financing overhangs, and validates a complement-pathway mechanism increasingly viewed as one of the next competitive frontiers in immunology. The deal, first signed in mid-October, brings Omeros $240 million at closing … Read more
Korea delivered two breakthrough reimbursement decisions, opening transformative access to Ultomiris for refractory generalized myasthenia gravis and elevating Jemperli to first-line status in dMMR/MSI-H endometrial cancer.
The Reimbursement Landscape Recalibrates As we pause for the Thanksgiving holiday, a sincere thank-you to our readers and partners for your continued engagement. This week’s update reflects a period of meaningful policymaking momentum across major global agencies. Across the U.S., UK, France, Canada and Thailand, agencies delivered firm, directional decisions that shape how hospitals, clinics … Read more
Reimbursement Momentum Favours SKYRIZI, Tagrisso and Cosentyx Friday brought major reimbursement shifts in Canada and Korea, recalibrating near-term access in inflammatory bowel disease, EGFR-mutated lung cancer and hidradenitis suppurativa. AbbVie secured a major win in Canada as SKYRIZI moved closer to funded access for ulcerative colitis. In Korea, reimbursement recalibration strengthened Tagrisso’s advantage over Leclaza … Read more